Jenburkt Pharmaceuticals Limited Fundamental Analysis (BSE: JENBURPH.BO)
Jenburkt Pharmaceuticals Limited Fundamental Analysis (BSE: JENBURPH.BO)
Jenburkt Pharmaceuticals Limited (BSE: JENBURPH.BO) shows moderate financial fundamentals with a PE ratio of 13.96, profit margin of 19.46%, and ROE of 17.28%. The company generates $1.7B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 64.8/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze JENBURPH.BO's fundamental strength across five key dimensions:
Efficiency Score
WeakJENBURPH.BO struggles to generate sufficient returns from assets.
Valuation Score
ModerateJENBURPH.BO shows balanced valuation metrics.
Growth Score
ModerateJENBURPH.BO shows steady but slowing expansion.
Financial Health Score
ModerateJENBURPH.BO shows balanced financial health with some risks.
Profitability Score
ModerateJENBURPH.BO maintains healthy but balanced margins.
Key Financial Metrics
Is JENBURPH.BO Expensive or Cheap?
P/E Ratio
JENBURPH.BO trades at 13.96 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, JENBURPH.BO's PEG of 11.53 indicates potential overvaluation.
Price to Book
The market values Jenburkt Pharmaceuticals Limited at 2.33 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 10.17 times EBITDA. This signals the market has high growth expectations.
How Well Does JENBURPH.BO Make Money?
Net Profit Margin
For every $100 in sales, Jenburkt Pharmaceuticals Limited keeps $19.46 as profit after all expenses.
Operating Margin
Core operations generate 22.39 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $17.28 in profit for every $100 of shareholder equity.
ROA
Jenburkt Pharmaceuticals Limited generates $0.00 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Jenburkt Pharmaceuticals Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Jenburkt Pharmaceuticals Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
JENBURPH.BO converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
13.96
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
11.53
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.33
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.72
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.00
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.17
vs 25 benchmark
ROA
Return on assets percentage
0.00
vs 25 benchmark
ROCE
Return on capital employed
0.00
vs 25 benchmark
How JENBURPH.BO Stacks Against Its Sector Peers
| Metric | JENBURPH.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 13.96 | 32.02 | Better (Cheaper) |
| ROE | 17.28% | 569.00% | Weak |
| Net Margin | 19.46% | 29948.00% | Weak |
| Debt/Equity | 0.00 | 0.53 | Strong (Low Leverage) |
| Current Ratio | 0.00 | 5.67 | Weak Liquidity |
| ROA | 0.00% | -98.00% (disorted) | Weak |
JENBURPH.BO outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Jenburkt Pharmaceuticals Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation